Biotech and Pharma Industry News | BioPharma Dive
WEBThe withdrawal comes as trial results indicate safety concerns with the drug, Oxbryta, which was first approved in the U.S. in 2019. BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Meso Scale Discovery (MSD): An immunoassay platform with …
WEBFeb 22, 2022 · ADVANTAGES. Sensitivity, Range and Ease-of-Use: In comparison to a conventional ELISA, MSD has higher sensitivity (LLOD 0.1-1.4 pg/mL) and a larger dynamic detection range (0.1-10 pg/mL).In addition, MSD has an efficient low volume sampling (1-25 μ L) and minimized matrix effect aiding in simultaneous multiplex detection with high precision. . Furthermore, MSD has simpler protocols, reduced ...
Novartis wins FDA approval for new heart drug, but faces uphill …
WEBDec 22, 2021 · Novartis priced Leqvio at $3,250 per dose for U.S. sale, meaning the first year of treatment will cost $9,750 and subsequent years $6,500. That’s slightly higher than the $5,400-per-year price that the Institute for Clinical and Economic Review, a watchdog group on drug costs, said would be cost effective for Leqvio when used broadly, but ...
Pharma News | BioPharma Dive
WEBOct 4, 2024 · The top biopharma conferences in 2025. Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch in 2025. By BioPharma Dive staff • Oct. 1, 2024. News roundup.
Radiopharmaceuticals for cancer: Making radiation precise
WEBAug 15, 2023 · When the Food and Drug Administration approved a new prostate cancer drug last year, it validated a bet made by Novartis to acquire the drug’s maker, Endocyte. The decision was also another step forward for a long-studied research field that appears to finally be coming of age. The medicine, Pluvicto, is known as a “radiopharmaceutical.”.
BioMarin finally secures FDA approval of hemophilia gene therapy
WEBJun 29, 2023 · The Food and Drug Administration approved on Thursday the first gene therapy for the most common form of hemophilia, clearing the way for what patients, doctors and the medicine’s developer hope could be a one-time treatment for the rare bleeding disorder. BioMarin Pharmaceutical, the California …
The biopharma industry outlook on 2024: Guarded optimism for a …
WEBPublished Jan. 16, 2024. Ned Pagliarulo Lead Editor. Brian Tucker / BioPharma Dive. Guarded optimism seems to be the mood of the biopharmaceutical industry to start 2024. Last year brought a stock market slide and layoffs for more than 150 drug companies. Financial and regulatory headwinds, like the March collapse of Silicon Valley Bank and a ...
Akero shares soar as NASH drug succeeds in mid-stage trial
WEBSep 13, 2022 · Akero Therapeutics’ shares more than doubled in early trading on Tuesday after the company said an experimental medicine reduced the internal scarring of patients with the fatty liver disease nonalcoholic steatohepatitis in a mid-stage clinical trial.. Both tested doses of Akero’s drug, known as efruxifermin, met the study’s main goal, producing a statistically significant improvement in ...
Two decades and $200 billion: AbbVie’s Humira monopoly nears …
WEBMar 17, 2022 · All told, AbbVie filed about 250 patent applications for Humira in the U.S., 90% of them following the drug's 2002 approval, according to the advocacy group Initiative for Medicines, Access & Knowledge. One hundred and thirty have been granted. The strengthened patent shield has stretched AbbVie's legal monopoly in the U.S. for six years beyond the expiration of Humira's main patent in 2016.
Novo’s latest obesity pill spurs major weight loss in small trial
WEBMar 7, 2024 · A newer drug Novo’s working on, CagriSema, helped obese people lose 17% of their body weight at 20 weeks, while an injectable from Viking Therapeutics was associated with 15% weight loss in 13 weeks. A pill Lilly has in Phase 3 testing, meanwhile, hit 13% weight loss at 26 weeks. Structure Therapeutics’ experimental pill produced 5% …